Pregledni rad

CARDIORENAL SYNDROME TYPE 2 – LITERATURE REVIEW

DRAGAN NOVOSEL ; Klinička bolnica Osijek, Klinika za internu medicinu, Odjel za kardiovaskularne bolesti, Osijek, Hrvatska
NIKOLINA BAŠIĆ-JUKIĆ ; Klinički bolnički centar Zagreb, Klinika za nefrologiju, arterijsku hipertenziju, dijalizu i transplantaciju, Zagreb, Hrvatska
ZORIN MAKAROVIĆ ; Klinička bolnica Osijek, Klinika za internu medicinu, Odjel za kardiovaskularne bolesti, Osijek, Hrvatska
SANDRA MAKAROVIĆ ; Klinička bolnica Osijek, Klinika za internu medicinu, Odjel za kardiovaskularne bolesti, Osijek, Hrvatska
PETAR KES ; Klinički bolnički centar Zagreb, Klinika za nefrologiju, arterijsku hipertenziju, dijalizu i transplantaciju, Zagreb, Hrvatska

Sažetak

We performed literature search in the Pubmed database in July 2013. The key word used for search was cardiorenal syndrome type 2, limited to English language and humans. Over the last decade, a significant advance in the understanding of the cardiorenal syndrome has been achieved. However, precise pathogenesis remains to be clarified. Current treatment in postponing progression of cardiorenal syndrome type 2 is not efficient, although novel drugs like levosimendan and tezosentan seem promising. Future research is necessary to determine their role in the treatment of cardiorenal syndrome type 2.

Ključne riječi

cardiorenal syndrome type 2; chronic renal failure; chronic heart failure

Hrčak ID:

126808

URI

https://hrcak.srce.hr/126808

Datum izdavanja:

14.9.2014.

Podaci na drugim jezicima: hrvatski

Posjeta: 1.925 *